Seeking Alpha

Cyclacel Pharmaceuticals jumps on Janney initiation

Cyclacel Pharmaceuticals (CYCC) rises 5% premarket (on top of 10% in Monday's regular session) in what looks like a reaction to an initiation (Buy) at Janney Montgomery.

Price target is $10.

Bullish call is more than likely tied to the company's Phase 3 AML candidate sapacitabine.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs